SCHEMBL11943402

SCHEMBL11943402

COc1ccc(CCOc2c(N3CCN(Cc4ccccc4O)CC3)cnn(-c3ccccc3)c2=O)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMO Q99835 2/20 0.49
▸ SMN1; SMN2 Q16637 3/20 0.46
▸ ALDH1A1 P00352 3/20 0.46
▸ NPBWR1 P48145 4/20 0.44
▸ CYP1A2 P05177 1/20 0.44
▸ CYP3A4 P08684 1/20 0.44
▸ CYP2C9 P11712 1/20 0.44
▸ CYP2C19 P33261 1/20 0.44
▸ NPSR1 Q6W5P4 1/20 0.44
▸ LMNA P02545 3/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ MAPK1 P28482 1/20 0.42
▸ NTSR1 P30989 1/20 0.42
▸ HTT P42858 1/20 0.42
▸ MCHR1 Q99705 2/20 0.42
▸ KMT2A Q03164 2/20 0.41
▸ DCTPP1 Q9H773 1/20 0.41
▸ RXFP1 Q9HBX9 1/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ GAA P10253 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14080964 0.92 NPBWR1 (0.43) SMOSMN1; SMN2ALDH1A1NPBWR1LMNA
SCHEMBL11943359 0.89 ALDH1A1 (0.49) SMOSMN1; SMN2ALDH1A1NPBWR1CYP1A2
SCHEMBL11943393 0.88 NPBWR1 (0.47) SMOSMN1; SMN2ALDH1A1NPBWR1CYP1A2
SCHEMBL11943348 0.88 SMO (0.47) SMOSMN1; SMN2ALDH1A1NPBWR1CYP1A2
SCHEMBL11943430 0.87 ALDH1A1 (0.45) SMOSMN1; SMN2ALDH1A1NPBWR1CYP1A2
SCHEMBL11943349 0.86 SMO (0.49) SMOSMN1; SMN2ALDH1A1NPBWR1CYP1A2
SCHEMBL11943378 0.86 ALDH1A1 (0.48) SMOSMN1; SMN2ALDH1A1NPBWR1CYP1A2
SCHEMBL11943421 0.86 SMO (0.54) SMOSMN1; SMN2ALDH1A1NPBWR1CYP1A2
SCHEMBL11943374 0.85 MCHR1 (0.56) SMOSMN1; SMN2ALDH1A1NPBWR1CYP1A2
SCHEMBL11943424 0.85 SMO (0.44) SMOSMN1; SMN2ALDH1A1NPBWR1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-20100158992-A1 PIPERAZINE-SUBSTITUTED PYRIDAZINONE DERIVATIVES USEFUL AS GLUCAN SYNTHASE INHIBITORS SCHERING CORPORATION (US) 2010-06-24 — — US disclosed
US-20100158992-A1 PIPERAZINE-SUBSTITUTED PYRIDAZINONE DERIVATIVES USEFUL AS GLUCAN SYNTHASE INHIBITORS SCHERING CORPORATION (US) 2010-06-24 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed
WO-2008115385-A2 PIPERAZINE-SUBSTITUTED PYRIDAZINONE DERIVATIVES USEFUL AS GLUCAN SYNTHASE INHIBITORS SCHERING CORPORATION (US) 2008-09-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors MAN2A1, GYS2, MANBA SMO 4431/4885SMN1; SMN2 3911/4885ALDH1A1 2437/4885
US-20100158992-A1 PIPERAZINE-SUBSTITUTED PYRIDAZINONE DERIVATIVES USEFUL AS GLUCAN SYNTHASE INHIBITORS DPM1, GMPS, MAN2A1 SMO 3100/4885SMN1; SMN2 3332/4885ALDH1A1 2003/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback